# A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults

> **NCT05385471** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Oxford** · enrollment: 36 (estimated)

## Conditions studied

- Malaria, Falciparum

## Interventions

- **BIOLOGICAL:** Matrix M with R78C and/or RH5.1

## Key facts

- **NCT ID:** NCT05385471
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-13
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05385471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05385471, "A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05385471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*